Yi X, et al. - Researchers performed a two-center, randomized controlled study to examine the relationship between CYP2C19*2 variants and early neurologic deterioration (END), and the efficacy of antiplatelet therapy for END prevention according to CYP2C19*2 genotypes in patients with ischemic stroke (IS). They analyzed data from 570 IS patients who were randomized to a clopidogrel plus aspirin group or an aspirin alone group between August 2009 and December 2011. Study findings suggested that dual therapy with clopidogrel and aspirin might be satisfactory for prevention of END in carriers of CYP2C19 reduced-function alleles, but not for noncarriers. The results obtained from the study could be helpful to guide precise antiplatelet therapy and reduce the risk of END.